The Parkinson's disease market is expected to grow steadily, driven by the recent approval of AbbVie's JUVMO along with the rising prevalence of the ...
Deutetrabenazine significantly reduced chorea severity over 16 weeks in a prospective study of Chinese adults with Huntington disease (HD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results